Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) publishes new interim data from Part A of its second-phase TACTI-002 trial showing “favourable” antitumour activity for its eftilagimod alpha (efti) drug
  • The company has published the data in an abstract at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting
  • The company will now present data from all 114 patients with a more recent data cut off even though the abstract contains data from the first 75 patients with a data cut off of January 2022
  • The company says the results show an improved disease control rate of 73.3 per cent compared to 66.7 per cent at ASCO 2021
  • IMM shares last traded at 39 cents on May 26

Immutep (IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing “favourable” antitumour activity for its eftilagimod alpha (efti) drug.

The published data includes results that found efti, with pembrolizumab, showed the antitumor activity in first-line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022. The drug also continued to show safety and tolerability.

Immutep has published the data in an abstract at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting.

Data from the trial will be presented on June 3.

While the ASCO abstract only contains data from the first 75 patients with a data cut-off of January 2022, Immutep’s June presentation will include data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from Immutep.

The company said efti and pembrolizumab showed an overall response rate (ORR) of 37.3 per cent as assessed by local read based on 75 patients and compared to 36.1 per cent at ASCO 2021.

Further, results showed an improved disease control rate of 73.3 per cent compared to 66.7 per cent at ASCO 2021.

Immutep has also announced the publication of an abstract for the design of the ongoing phase IIB TACTI-003 trial that will be presented as a trial-in-progress poster presentation at ASCO 2022.

IMM shares last traded at 39 cents on May 26.

IMM by the numbers
More From The Market Herald
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…
Ten Sixty Four (ASX:X64) - Outgoing Managing Director, Paul Ryan Welker

" Ten Sixty Four (ASX:X64) terminates services agreement of former MD, Paul Ryan Welker

Ten Sixty Four (ASX:X64) has terminated the executive services agreement of former Managing Director Paul Ryan…

" M3 Mining (ASX:M3M) identifies drill targets at Edjudina

M3 Mining (ASX:M3M) has identified prospective gold-in-soil anomalies at the Edjudina gold project 150 kilometres northeast…

" Good Drinks Australia (ASX:GDA) commences the sale of Molson Coors and Magners

Good Drinks Australia (ASX:GDA) begins to sell the Miller Chill, Miller Genuine Draught, Coors, Molson Canadian…